Julian Lin returns to discuss two of his favorite cannabis plays - a REIT and an MSO. Cannabis investing philosophy (valuations should drive capital allocations).
Q1 2022 Revenue of $111.2 Million, up 90% YoY Q1 2022 Adjusted EBITDA of $19.5 Million, up 6% YoY US GAAP Operating Loss of $21.1 Million and $8.4 Million for Q1 2022 and. #ayr #ayrwellness #AYRWF